What is RxSight, Inc.'s SG&A?

RxSight, Inc. (RXST) reported SG&A of $31.86M in Q1 2026.

How has RxSight, Inc.'s SG&A changed year-over-year?

RxSight, Inc.'s SG&A increased by 11.2% year-over-year, from $28.64M to $31.86M.

What is the long-term trend for RxSight, Inc.'s SG&A?

Over 4 years (2021 to 2025), RxSight, Inc.'s SG&A has grown at a 36.1% compound annual growth rate (CAGR), from $32.81M to $112.65M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

RxSight, Inc. RXST SG&A

SG&A at other companies

Johnson & JohnsonJNJ

$6.03B+18.0%

LENSAR, Inc.LNSR

$2.53M-77.3%

Precision Optics CorporationPOCI

$1.85M-17.4%

Bausch + LombBLCO

$544M-3.4%

GlaukosGKOS

$92.94M+31.5%

Other financials

Income statement

See full

Revenue$30.9M-18.5%

Gross profit$23.5M-17.1%

Operating income-$17.8M-67.0%

Net income-$15.9M-93.9%

EPS (diluted)-$0.38-90.0%

Balance sheet

See full

Cash & equivalents$17.6M-37.2%

Total debt$10.8M-10.1%

Total equity$267.3M-4.3%

Total assets$304.0M-2.9%

Cash flow

See full

Operating cash flow-$10.9M-23.3%

CapEx$759.0K+32.0%

Free cash flow-$11.7M-23.8%

Valuation

See full

Market cap$232.23M-56.8%

Enterprise value$225.49M-55.7%

P/S1.8×-1.8×

Profitability

See full

Gross margin77%+5.1pp

Operating margin-43.4%+128pp

Net margin-36.6%-867pp

FCF margin-16.9%+4.9pp

Returns & leverage

See full

Return on equity-17.1%+12.6pp

Debt / equity0×0.0×

Current ratio10.2×-2.5×

Where this comes from

Reported directly by RxSight, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: RxSight, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about RxSight, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is RxSight, Inc.'s SG&A?: RxSight, Inc. (RXST) reported SG&A of $31.86M in Q1 2026.
How has RxSight, Inc.'s SG&A changed year-over-year?: RxSight, Inc.'s SG&A increased by 11.2% year-over-year, from $28.64M to $31.86M.
What is the long-term trend for RxSight, Inc.'s SG&A?: Over 4 years (2021 to 2025), RxSight, Inc.'s SG&A has grown at a 36.1% compound annual growth rate (CAGR), from $32.81M to $112.65M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.